Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: Pharmacokinetic study and Tc-99m-albumin microcolloid technique

Citation
L. Cattel et al., Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: Pharmacokinetic study and Tc-99m-albumin microcolloid technique, ANTICANC R, 21(3C), 2001, pp. 2243-2248
Citations number
20
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTICANCER RESEARCH
ISSN journal
02507005 → ACNP
Volume
21
Issue
3C
Year of publication
2001
Pages
2243 - 2248
Database
ISI
SICI code
0250-7005(200105/06)21:3C<2243:MMDHPO>2.0.ZU;2-C
Abstract
Background: The kinetics of melphalan leakage from extracorporeal fluid to the peripheral blood was studied in ten patients undergoing hyperthermic is olation perfusion of the lower limbs as an adjuvant treatment in high-fisk melanoma. Materials and Methods: Systemic leakage was monitored by a new te chnique using Tc-99m-albumin microcolloid. Serial samples were drawn from a peripheral vein and from the perfusion circuit during surgical treatment a nd analysed by HPLC. Results: The leakage measured with Tc-99m-albumin micr ocolloid ranged from 1.5 to 18 %/h (mean 8 %/h), The average concentrations in the perfusate were 200-300-fold those found in the systemic circulation . A good correlation (R=0.945) was obtained between systemic AUC (0 to 1 ho ur) and leakage measured through the Tc-99m procedure. Negligible toxicity was found and the survival rate yielded 92% of objective response. Conclusi on: By studying the pharmacokinetic data of melphalan in the circuit and in the systemic circulation, we were able to validate the Tc-99m procedure us ed during clinical perfusion. Moreover, considering the efficiency of the s ystem as well as the minimum toxicity and the high survival rate, a reducti on of perfusion time may be considered.